MedTrace Logo

The Use of Suprachoroidal Triamcinolone Acetonide to Treat Macular Edema in Retinal Vein Occlusion

NCT05038072 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-09-08

No results posted yet for this study

Summary

This prospective non-randomized open-label interventional study aimed to evaluate feasibility in regard to potential efficacy and safety of triamcinolone acetonide (TA) injected in the suprachoroidal space (SCS) as a promising therapeutic route that provides a better bioavailability, longer sustained duration of action, and thus improved patients' compliance for the treatment of macular edema due to retinal vein occlusion (RVO).

Conditions

  • Macular Edema
  • Retinal Vein Occlusion

Interventions

DRUG

suprachoroidal injection of Triamcinolone Acetonide.

4 mg /0.1 ml TA was injected in the SCS using an individualized microinjector according to scleral thickness measured by anterior segment OCT (AS-OCT) at the injection point (4 mm from the limbus in the inferotemporal quadrant).

Sponsors & Collaborators

  • Damascus University

    lead OTHER

Principal Investigators

  • Boushra M Ali, M.D., MRCSEd · Resident , Department of Ophthalmology, Faculty of Medicine, Damascus University

  • Arwa M Azmeh, Ph.D. · Professor of Ophthalmology, Department of Ophthalmology, Faculty of Medicine, Damascus University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-25
Primary Completion
2020-11-22
Completion
2021-02-28

Countries

  • Syria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05038072 on ClinicalTrials.gov